Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Acura Gains as Pfizer Says Pill Reaches Market: Chicago Mover

Don't Miss Out —
Follow us on:

Jan. 24 (Bloomberg) -- Acura Pharmaceuticals Inc., a maker of technology to deter drug abuse, rose after its short-acting painkiller marketed by Pfizer Inc. became commercially available.

Acura gained 8.1 percent to $4.02 at 4 p.m. in New York. The shares have gained 33 percent in the last 12 months.

The short-acting oxycodone pill Oxecta with tamper-resistant properties uses Acura’s Aversion Technology, exclusively licensed to Pfizer in the U.S., Canada and Mexico, the Palatine, Illinois-based company said yesterday in a statement. Acura receives royalties from 5 percent to 25 percent for the drug, which will be sold in bottles of 100 tablets.

“The commercial availability of Oxecta is an important milestone and we are pleased Pfizer continues to advance the commercialization plan for Oxecta,” said Bob Jones, chief executive officer of Acura, in the news release.

Oxteca acts in a manner similar to opioids and narcotics to help ease people from addiction, the company said in a statement. The tablet includes technology that makes it difficult to abuse or misuse.

To contact the reporter on this story: Sarah Frier in New York at sfrier1@bloomberg.net;

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.